MorphoSys to Present at Three Investor Conferences in June
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that its management will give company presentations at three
upcoming investor conferences in June 2009.
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, will
present at BioEquity Europe 2009, being held June 9-10 in Munich,
Germany, and at the Jefferies 3rd Annual Healthcare Conference, being
held June 17-18 in New York, USA.
Dave Lemus, Chief Financial Officer of MorphoSys AG, will present at
the Deutsche Bank German & Austrian Corporate Conference, being held
June 23 in Frankfurt, Germany.
BioEquity Europe 2009
Date: Tuesday, June 9, 2009
Time: 02:30pm BST (09:30am EDT; 03:30pm CET)
Venue: Hilton Munich Park Hotel, Munich, Germany
Jefferies 3rd Annual Healthcare Conference
Date: Thursday, June 18, 2009
Time: 08:15 pm BST (03:15 pm EDT; 09:15 pm CET)
Venue: Mandarin Oriental Hotel, New York, USA
Deutsche Bank German & Austrian Corporate Conference
Date: Tuesday, June 23, 2009
Time: 11:30am BST (06:30am EDT; 12:30pm CET)
Venue: Hilton Hotel, Frankfurt, Germany
Presentations as well as live and archived webcasts of the
presentations will be provided at www.morphosys.com.
For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Senior
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.